Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5379789 | 1.00 | KMT2A (0.53) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5379214 | 1.00 | KMT2A (0.53) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL295762 | 1.00 | KMT2A (0.53) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5379742 | 1.00 | KMT2A (0.53) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12087990 | 0.88 | CHRM2 (0.50) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12151312 | 0.88 | CHRM2 (0.50) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5011861 | 0.86 | KMT2A (0.47) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL11146489 | 0.86 | KMT2A (0.47) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL26645908 | 0.85 | KMT2A (0.47) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12091646 | 0.83 | CHRM2 (0.47) | KMT2ACHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268228-B2 | Optically active aziridine-2-carboxylate derivatives and a process for preparing them | IMAGENE CO., LTD. (KR) | 2007-09-11 | — | — | US | disclosed |
| EP-1309550-A4 | OPTICALLY ACTIVE AZIRIDINE-2-CARBOXYLATE DERIVATIVES AND A PROCESS FOR PREPARING THEM | CHEMBIONEX CO LTD (KR) | 2004-07-07 | — | — | EP | disclosed |
| US-20040030133-A1 | Optically active aziridine-2-carboxylate derivatives and a process for preparing them | IMAGENE CO. LTD. (KR) | 2004-02-12 | — | — | US | disclosed |
| EP-1309550-A1 | OPTICALLY ACTIVE AZIRIDINE-2-CARBOXYLATE DERIVATIVES AND A PROCESS FOR PREPARING THEM | Chembionex Co., Ltd (KR) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012186-A1 | OPTICALLY ACTIVE AZIRIDINE-2-CARBOXYLATE DERIVATIVES AND A PROCESS FOR PREPARING THEM | CHEMBIONEX CO., LTD. (KR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030133-A1 | Optically active aziridine-2-carboxylate derivatives and a process for preparing them | HRH2, HRH1, DDC | KMT2A 648/4885CHRM2 13/4885CHRM4 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.